Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate in HIV-1-infected Adolescents Failing Antiretroviral Therapy

2015 ◽  
Vol 34 (4) ◽  
pp. 398-405 ◽  
Author(s):  
Marinella Della Negra ◽  
Aroldo Prohmann De Carvalho ◽  
Maria Zilda De Aquino ◽  
Jorge Andrade Pinto ◽  
Marcos Tadeu Nolasco Da Silva ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Tenofovir Disoproxil Fumarate ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Hiv 1

scholarly journals Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

AIDS ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Peter Ackerman ◽  
Melanie Thompson ◽  
Jean-Michel Molina ◽  
Judith Aberg ◽  
Isabel Cassetti ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Term Efficacy ◽  
Hiv 1

Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients

2017 ◽  
Vol 49 (5) ◽  
pp. 530-534 ◽  
Author(s):  
Massimo Fasano ◽  
Paolo Maggi ◽  
Armando Leone ◽  
Anna Volpe ◽  
Jose Ramon Fiore ◽  
...  
Keyword(s):  
Tenofovir Disoproxil Fumarate ◽  
Efficacy And Safety ◽  
Term Efficacy

scholarly journals Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study

2016 ◽  
Vol 17 (1) ◽  
pp. 17-28 ◽  
Author(s):  
Eugénio Teófilo ◽  
Nuno Rocha-Pereira ◽  
Birger Kuhlmann ◽  
Antonio Antela ◽  
Heribert Knechten ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Term Efficacy ◽  
Treatment Naïve ◽  
Hiv 1 ◽  
Renal Safety

scholarly journals Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years

2014 ◽  
Vol 17 ◽  
pp. 19767 ◽  
Author(s):  
Brian Gazzard ◽  
Pierre Marie Girard ◽  
Giovanni Di Perri ◽  
Joel Gallant ◽  
William Towner ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Term Efficacy ◽  
Treatment Naïve ◽  
Hiv 1

Long-Term Efficacy and Safety of Tipranavir Boosted With Ritonavir in HIV-1-Infected Patients Failing Multiple Protease Inhibitor Regimens

2007 ◽  
Vol 45 (4) ◽  
pp. 401-410 ◽  
Author(s):  
Martin Markowitz ◽  
Leonard N Slater ◽  
Robert Schwartz ◽  
Powel H Kazanjian ◽  
Bruce Hathaway ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Hiv 1

Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection

AIDS ◽  
2002 ◽  
Vol 16 (10) ◽  
pp. 1432-1433 ◽  
Author(s):  
Sandro Vento ◽  
Massimiliano Lanzafame ◽  
Francesca Cainelli ◽  
Federica Faggian ◽  
Ercole Concia ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Reverse Transcriptase ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Transcriptase Inhibitor ◽  
Term Efficacy ◽  
Reverse Transcriptase Inhibitor ◽  
Hiv 1

scholarly journals Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults

2019 ◽  
Vol 18 ◽  
pp. 232595821882196
Author(s):  
Oche O. Agbaji ◽  
Isaac O. Abah ◽  
Augustine O. Ebonyi ◽  
Zumnan M. Gimba ◽  
Esla E. Abene ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Renal Impairment ◽  
Tenofovir Disoproxil Fumarate ◽  
Treatment Guidelines ◽  
Hiv Treatment ◽  
Resource Limited ◽  
Continued Use ◽  
Tenofovir Alafenamide ◽  
Hiv 1

Objectives and Method: There are growing concerns of tenofovir disoproxil fumarate (TDF)–associated renal toxicity. We evaluated the effect of long-term TDF exposure on renal function in a cohort of HIV-1-infected Nigerians between 2006 and 2015. Multivariate logistic regression was used to identify predictors of renal impairment at different time over 144 weeks of antiretroviral therapy (ART). Results: Data of 4897 patients, median age 42 years (interquartile range: 36-49), and 61% females were analyzed. The prevalence of renal impairment increased from 10% at week 24 to 45% at 144 weeks in TDF-exposed participants compared to an increase from 8% at 24 weeks to 14% at 144 weeks in TDF-unexposed participants. Tenofovir disoproxil fumarate exposure predicted the risk of renal impairment at 144 weeks of ART (odds ratio: 2.36; 95% confidence interval: 1.28-4.34). Conclusion: Long-term exposure to TDF-based ART significantly increases the likelihood of renal impairment. The continued use of TDF-based regimen in our setting should be reviewed. We recommend the urgent introduction of tenofovir alafenamide–based regimen in the HIV treatment guidelines of Nigeria and other resource-limited countries.

Sign in / Sign up

Export Citation Format

Share Document